Exelixis Inc

25 sept. 2026, 23:20 UTC

Exelixis Inc is lower in after-market trading, retracing from an early gain and reflecting a decline since Friday's close.

24 sept. 2026, 20:01 UTC

Exelixis Inc is advancing, peaking in mid-afternoon while remaining above its 20-day moving average and near the upper end of its one-month range.

23 sept. 2026, 20:07 UTC

Exelixis Inc shares fell significantly on Wednesday, having briefly spiked earlier in the session, reflecting a lack of momentum in either direction.

22 sept. 2026, 20:06 UTC

Exelixis Inc is gaining today, building on Monday's momentum, with the stock remaining above its 20-day moving average and near its one-month range's upper end.

21 sept. 2026, 23:25 UTC

Exelixis Inc is trading modestly lower in after-market hours, continuing a decline seen over the past three sessions after reaching a session high.

18 sept. 2026, 20:06 UTC

Exelixis Inc's shares fell sharply after reaching a notable peak earlier in the session, while remaining above the 20-day moving average.

16 sept. 2026, 20:07 UTC

Exelixis Inc shares fell sharply, retracing from an early peak in cumulative return amid unusually high market volume on Wednesday.

15 sept. 2026, 20:07 UTC

Exelixis Inc. shares are higher as the company expands CABOMETYX in renal cell carcinoma and neuroendocrine tumors, reflecting investor confidence amid broader market concerns.

14 sept. 2026, 20:07 UTC

Exelixis shares are rising after BMO indicated the FDA's PDUFA date extension for Zanzalintinib is procedural, maintaining a $55 price target.

11 sept. 2026, 20:01 UTC

Exelixis shares are lower as the FDA extends the review period for zanzalintinib by three months, now set for March 3, 2027.

10 sept. 2026, 20:07 UTC

Exelixis Inc shares are lower amid market reaction to the European Central Bank's interest rate hike. The stock briefly recovered earlier in the session.

9 sept. 2026, 20:07 UTC

Exelixis announced a $2 million milestone payment to Adagene for preclinical progress on the XB404 program, boosting shares in Wednesday's session.

8 sept. 2026, 19:51 UTC

Exelixis Inc shares are lower today, influenced by a decline in the Biotechnology sub-sector, breaking a trend of higher daily closes since Friday.

3 sept. 2026, 20:07 UTC

Exelixis Inc is advancing during Thursday's session, maintaining upward momentum since Wednesday. No specific news was identified to explain the price movement.

2 sept. 2026, 23:56 UTC

Exelixis Inc shares are higher in after-market trading, though no specific news was identified. The broader market reacted to weaker ADP payroll data.

1 sept. 2026, 23:06 UTC

Exelixis Inc. shares are lower in after-market hours, with no specific news identified for the decline amid broader market concerns.

31 aug. 2026, 22:16 UTC

Exelixis shares are higher in after-market hours, rebounding from a slight dip earlier. This follows broader market reactions to Federal Reserve comments on inflation.

28 aug. 2026, 23:01 UTC

Exelixis Inc shares are lower in after-market hours, continuing a trend of declines amid rising interest rate hike expectations affecting the biotechnology sector.

27 aug. 2026, 20:07 UTC

Exelixis Inc shares are trading lower amid broader market declines. The cumulative return has reached a low point, with no specific news driving the movement.

26 aug. 2026, 23:01 UTC

Exelixis Inc's shares are higher in after-market trading, reaching a high of 0.73% above Wednesday's close and 5.12% above its 20-day moving average.

25 aug. 2026, 19:45 UTC

Exelixis Inc is trading higher amid a favorable market backdrop of declining crude oil prices and decreasing Treasury yields, continuing its upward momentum.

24 aug. 2026, 19:36 UTC

Exelixis Inc. shares are modestly higher since Friday's close, trading within the middle of their one-month range and above the 20-day moving average.

21 aug. 2026, 20:06 UTC

Exelixis Inc shares are higher today, continuing a trend since Thursday's close. Broader biotechnology sector gains may be contributing to the movement.

20 aug. 2026, 23:36 UTC

Exelixis Inc's shares are higher in after-market trading, reflecting notable strength despite no specific news to explain the price action.

19 aug. 2026, 19:36 UTC

BMO Capital initiated coverage on Exelixis Inc with a Market Perform rating and a price target of $54. Shares are trading higher today.

18 aug. 2026, 23:56 UTC

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

13 aug. 2026, 19:46 UTC

Exelixis Inc's shares are higher Thursday, supported by positive investor sentiment despite a slight pullback from earlier gains. Initial jobless claims rose to 209k.

12 aug. 2026, 19:51 UTC

Exelixis Inc shares are lower amid an investigation for potential securities law violations and a revenue shortfall of $628.7 million in Q2.

11 aug. 2026, 23:51 UTC

Exelixis Inc shares are lower in after-market hours, continuing a downward trend since Tuesday's close amid notable volatility and market anticipation of the CPI report.

10 aug. 2026, 23:01 UTC

Exelixis shares are lower in after-market trading amid scrutiny over a potential securities fraud investigation and lowered full-year revenue guidance.